Elutia names Pete Ligotti as CCO to launch NXT-41x in $1.5B breast surgery market
Elutia appointed Pete Ligotti as Chief Commercial Officer to spearhead the 2027 commercialization of NXT-41x, its next-generation antibiotic-eluting biomatrix targeting over 162,000 annual U.S. breast reconstruction procedures with 15-20% infection rates. The move positions Elutia to capture a share of the $1.5 billion domestic surgical mesh market.
1. Executive Appointment
Elutia appointed Pete Ligotti as Chief Commercial Officer to lead NXT-41x commercialization. He brings 20 years of commercial execution in complex surgical markets, having built Integra LifeSciences’ plastic and reconstructive surgery operation, scaled a European specialty surgical business to $180 million in four years, and driven a 40% revenue turnaround at NuVasive.
2. Product and Market Opportunity
NXT-41x is a next-generation antibiotic-eluting biomatrix built on Elutia’s validated drug-eluting platform, designed for plastic and reconstructive surgery. Over 162,000 breast reconstruction procedures occur annually in the U.S., with 15-20% infection rates despite mesh use in more than 80% of cases, representing a $1.5 billion market.
3. Commercial and Regulatory Strategy
Elutia anticipates FDA clearance for NXT-41x in 2027 and is developing market penetration and reimbursement plans. The company aims to replace legacy biologic meshes by offering a drug-eluting standard that reduces failure rates and improves clinical outcomes for post-mastectomy patients.